Lilly Points To Six-Month Growth Instead Of Pandemic Impacted Q2

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.

Covid19_Business_Impact
Lilly took the expected revenue hit during the second quarter but expects normalization during the second half

Eli Lilly and Company reported that the COVID-19 pandemic posed a negative impact on its second quarter sales and earnings on 30 July, with its three biggest products – Trulicity, Taltz and Jardiance – down or flat from the first quarter. But all three showed growth over the second quarter 2019 and Lilly maintains its overall trends are positive, citing 6% volume growth for the first six months of 2020 compared to the first half of 2019.

In addition, the pharma pointed to multiple clinical trial successes during the past quarter that should aid label-expansion efforts for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.